<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="641">
  <stage>Registered</stage>
  <submitdate>16/08/2005</submitdate>
  <approvaldate>16/08/2005</approvaldate>
  <nctid>NCT00131495</nctid>
  <trial_identification>
    <studytitle>Study of Transdermal Testosterone Patches in Menopausal Women With Low Libido</studytitle>
    <scientifictitle>A Randomized, Double-Blind, Placebo-controlled, Parallel-group, 52-week Study to Evaluate the Efficacy/Safety of Transdermal Patches Delivering Testosterone in Menopausal Women With Low Libido Not Receiving Estrogen Therapy</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2004031 and Yr 2 SB</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hypoactive Sexual Desire Disorder</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Testosterone (transdermal patches)
Treatment: drugs - Placebo patch

Placebo Comparator: 1 - Placebo patch

Experimental: 2 - Testosterone patch (300mcg/day, changed twice a week for one year


Treatment: drugs: Testosterone (transdermal patches)
Testosterone patch (300mcg/day, changed twice a week for one year

Treatment: drugs: Placebo patch
placebo patch changed twice a week for one year

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Total satisfying sexual activity over 24 weeks</outcome>
      <timepoint>6, 12, 24, 36, and 52 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Sexual desire</outcome>
      <timepoint>6, 12, 24, 36, and 52 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>personal distress</outcome>
      <timepoint>6, 12, 24, 36, and 52 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>other domains of the Profile of Female Sexual Function over 24 weeks</outcome>
      <timepoint>6, 12, 24, 36, and 52 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>mood, energy and well-being</outcome>
      <timepoint>6, 12, 24, 36, and 52 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>menopausal symptoms</outcome>
      <timepoint>6, 12, 24, 36, and 52 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Be a generally healthy surgically menopausal woman (12 months), 20 to 70 years of age,
             not receiving any systemic estrogen or estrogen progestin therapy

          -  Be a generally healthy naturally menopausal woman (2 years since last period), 40 to
             70 years of age, not receiving any systemic estrogen or estrogen progestin therapy.

          -  Be, in their own judgment, in a stable monogamous sexual relationship for at least one
             year prior to study entry that is perceived to be secure and communicative with the
             same partner who is sexually functional and physically present at least 50% of the
             time.

          -  Answer affirmatively to ALL of the following questions:

               1. Was the patient's sex life before menopause good and satisfying in general?

               2. Since menopause, has a meaningful loss in the level of desire for sex occurred?

               3. Since menopause, has a significant decrease in sexual activity occurred?

               4. Is the current level of desire for or interest in sex bothering or concerning?

               5. Is an increase in the level of interest in or desire for sex and sexual activity
                  desired?</inclusivecriteria>
    <inclusiveminage>20</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Female</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Physical limitations that would interfere with normal sexual function;

          -  Estrogen use in the last 12 weeks (vaginal estriol or low dose vaginal estradiol
             accepted)

          -  Use of any of the following medications:

               -  antiandrogen therapy or topical minoxidil (last 5 years),

               -  androgen therapy (past 3 months/implantable past 7 months),

               -  systemic corticosteroids,

               -  selective serotonin reuptake inhibitors (SSRIs),

               -  tricyclic anti-depressants,

               -  anti-androgens,

               -  systemic beta-blockers,

               -  anti-adrenergics,

               -  spironolactone,

               -  apomorphine,

               -  phosphodiesterase type 5 (PDE5) inhibitors (e.g., Viagra, tibolone or selective
                  estrogen receptor modulators (SERMs), including tamoxifen (last 12 weeks))

          -  Be experiencing any chronic or acute life stress relating to any major life change
             that may significantly interfere with sexual function;

          -  Have significant psychiatric disorder (including mild depressive disorder - Beck
             Depression Inventory-II score of &gt; 14;

          -  Have current severe dermatological problems or a known suspected hypersensitivity or
             allergy to any adhesive or any of the constituents of the transdermal testosterone
             patch

          -  Have evidence of or history of malignancy (estrogen dependent or any gynecological
             cancer) within the last 5 years;

          -  Have diabetes mellitus, active gallbladder disease, unstable thyroid disease, history
             of cerebrovascular disease, thrombo-embolic disorders, myocardial infarction or angina
             within the last 5 years or other significant organic disease that would prevent the
             patient from completing the study, or otherwise affect the outcome of the study.

          -  Have significant abnormal pretreatment laboratory parameters.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/07/2004</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>814</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/02/2007</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Monash Medical School, The Alfred Hospital - Prahran</hospital>
    <postcode>VIC 3181 - Prahran</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Warner Chilcott</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study is designed to evaluate the efficacy and safety of 2 doses of the transdermal
      testosterone patch in naturally or surgically menopausal women with low libido who are not
      receiving systemic estrogen or estrogen progestin therapy.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00131495</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Sue Davis, MD</name>
      <address>Monash Medical School, The Alfred Hospital</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>